These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23125835)

  • 1. Ocular drug delivery: a clue from nanotechnology.
    Bucolo C; Drago F; Salomone S
    Front Pharmacol; 2012; 3():188. PubMed ID: 23125835
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanotechnology in ocular drug delivery.
    Sahoo SK; Dilnawaz F; Krishnakumar S
    Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology in ocular delivery: current and future directions.
    Sultana Y; Maurya DP; Iqbal Z; Aqil M
    Drugs Today (Barc); 2011 Jun; 47(6):441-55. PubMed ID: 21695286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microspheres and Nanotechnology for Drug Delivery.
    Jóhannesson G; Stefánsson E; Loftsson T
    Dev Ophthalmol; 2016; 55():93-103. PubMed ID: 26501994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel strategies for anterior segment ocular drug delivery.
    Cholkar K; Patel SP; Vadlapudi AD; Mitra AK
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):106-23. PubMed ID: 23215539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of nanotechnology in control of human diseases: perspectives in ocular surface diseases.
    Rai M; Ingle AP; Gaikwad S; Padovani FH; Alves M
    Crit Rev Biotechnol; 2016 Oct; 36(5):777-87. PubMed ID: 26189355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities.
    El Hoffy NM; Abdel Azim EA; Hathout RM; Fouly MA; Elkheshen SA
    Eur J Pharm Sci; 2021 Mar; 158():105648. PubMed ID: 33227347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current nanotechnological strategies for treating glaucoma.
    Goyal G; Garg T; Rath G; Goyal AK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(5):365-405. PubMed ID: 25271557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology-Ocular Devices for Glaucoma Treatment: A Literature Review.
    Cardigos J; Ferreira Q; Crisóstomo S; Moura-Coelho N; Cunha JP; Pinto LA; Ferreira JT
    Curr Eye Res; 2019 Feb; 44(2):111-117. PubMed ID: 30309248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocrystal for ocular drug delivery: hope or hype.
    Sharma OP; Patel V; Mehta T
    Drug Deliv Transl Res; 2016 Aug; 6(4):399-413. PubMed ID: 27165145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent perspectives in ocular drug delivery.
    Gaudana R; Jwala J; Boddu SH; Mitra AK
    Pharm Res; 2009 May; 26(5):1197-216. PubMed ID: 18758924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prominence of the dosage form design to treat ocular diseases.
    Campos PM; Petrilli R; Lopez RFV
    Int J Pharm; 2020 Aug; 586():119577. PubMed ID: 32622806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
    Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
    Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of lipid nanoparticles to ocular drug delivery.
    Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug delivery to the eye: what benefits do nanocarriers offer?
    Joseph RR; Venkatraman SS
    Nanomedicine (Lond); 2017 Mar; 12(6):683-702. PubMed ID: 28186436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocarriers in ocular drug delivery: an update review.
    Wadhwa S; Paliwal R; Paliwal SR; Vyas SP
    Curr Pharm Des; 2009; 15(23):2724-50. PubMed ID: 19689343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnology-based strategies for treatment of ocular disease.
    Weng Y; Liu J; Jin S; Guo W; Liang X; Hu Z
    Acta Pharm Sin B; 2017 May; 7(3):281-291. PubMed ID: 28540165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Trends in Nanomedicine for Improving Ocular Drug Delivery: Light-Responsive Nanoparticles, Mesoporous Silica Nanoparticles, and Contact Lenses.
    Rodrigues FSC; Campos A; Martins J; Ambrósio AF; Campos EJ
    ACS Biomater Sci Eng; 2020 Dec; 6(12):6587-6597. PubMed ID: 33320633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISOPT
    Kompella UB; Domb A; Urtti A; Jayagopal A; Wilson CG; Tang-Liu D
    J Ocul Pharmacol Ther; 2019 Oct; 35(8):457-465. PubMed ID: 31259643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.
    Cholkar K; Patel A; Vadlapudi AD; Mitra AK
    Recent Pat Nanomed; 2012; 2(2):82-95. PubMed ID: 25400717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.